Cat. No.: DAB-0011887
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human |
Applications | WB, IHC, IF, Flow Cyt |
Product Description | Monoclonal antibody is produced by immunizing animals with human CD10/Neprilysin recombinant protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | MME |
UniProt No. | P08473 |
Gene ID | 4311 |
Gene Description | CD10, also known as neprilysin, common acute lymphoblastic leukemia antigen, or neutral endopeptidase, is a zinc-dependent transmembrane metallo-endopeptidase. CD10 cleaves peptides at the N-terminal side of hydrophobic amino acid residues and deactivates a variety of signaling peptides. CD10 was shown to be one of the markers for a natural killer cell-restricted progenitor in fetal and adult tissues. Studies also suggest CD10 as a phenotypic marker to distinguish mature neutrophils from immature neutrophils in patients with inflammation. In addition, CD10+GPR77+ carcinoma-associated fibroblasts promote tumor formation and chemoresistance. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at -20 °C. This product will freeze at -20 °C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. |
Storage Buffer | Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.